Parnax Lab

Parnax Lab Short-term Debt

The Short-Term Debt of Parnax Lab (506128.BO) as of Nov 14, 2026 is 359.58 M INR. In the previous year, Short-Term Debt was 432.14 M INR — a change of -16.79% (lower).

Short-term Debt

359.58 MINR

YoY

-16.79%

Last updated:

Short-Term Debt of Parnax Lab is 2025 359.58 M INR. Short-Term Debt of Parnax Lab was 2024 432.14 M INR. It decreases by -16.79% lower compared to the previous year.

The Parnax Lab Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
150.29 M INR
Jan 1, 2019
156.85 M INR
Jan 1, 2020
281.14 M INR
Jan 1, 2021
364.34 M INR
Jan 1, 2022
426.96 M INR
Jan 1, 2023
332.74 M INR
Jan 1, 2024
432.14 M INR
Jan 1, 2025
359.58 M INR
The Parnax Lab Short-term Debt history
YEARShort-term DebtYoY
359.58 MINR-16.79%
432.14 MINR+29.87%
332.74 MINR-22.07%
426.96 MINR+17.19%
364.34 MINR+29.59%
281.14 MINR+79.24%
156.85 MINR+4.37%
150.29 MINR-63.46%
411.33 MINR-1.55%
417.80 MINR+1.75%
410.60 MINR+23.24%
333.17 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

Short-Term Debt of Parnax Lab is 359.58 M INR in 2025.

Short-Term Debt of Parnax Lab changed from 432.14 M INR to 359.58 M INR, representing a -16.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Parnax Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Parnax Lab

All Key Metrics — Parnax Lab